Berikutnya

Putar otomatis

Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma

1 Tampilan • 07/18/23
Membagikan
Menanamkan
administrator
administrator
Pelanggan
0

William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.

Menampilkan lebih banyak
0 Komentar sort Sortir dengan
Komentar Facebook

Berikutnya

Putar otomatis